Everything below concerns anti-doping. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
== Actions == The Council announced a state of emergency in Port Sudan during tribal clashes which resulted in the death of 16 people on 26 August 2019. In November 2019, Abdalla Hamdok's government repealed all laws restricting women's freedom of dress, movement, association, work and study. On 22 April 2020, the transitional government issued an amendment to its criminal legislation which declares that anyone who performs female genital mutilation either in a medical establishment or elsewhere will be punished by three years' imprisonment and a fine.
Like those of vertebrates, octopus blood vessels are very elastic, with a resilience of 70% at physiologic pressures. They are primarily made of an elastic fiber called octopus arterial elastomer, with stiffer collagen fibers recruited at high pressure to help the vessel maintain its shape without over-stretching. Shadwick and Nilsson theorized that all octopus blood vessels may use smooth-muscle contractions to help move blood through the body, which would make sense in the context of them living under water with the attendant pressure. The elasticity and contractile nature of the octopus aorta serves to smooth out the pulsing nature of blood flow from the heart as the pulses travel the length of the vessel, while the vena cava serves in an energy-storage capacity. Stroke volume of the systemic heart changes inversely with the difference between the input blood pressure through the vena cava and the output back pressure through the aorta.
In 2015, Schumer was named one of Time magazine's 100 most influential people. Schumer was named to Barbara Walters' 10 Most Fascinating People for 2015. Schumer has received praise for addressing various social issues through comedy. Throughout 2015, several of Schumer's skits in Inside Amy Schumer went viral online, sparking editorials regarding sex, feminism, and rape culture. In June 2015, Monica Heisey of The Guardian criticized her for "a shockingly large blind spot around race". Schumer responded on Twitter, stating "I go in and out of playing an irreverent idiot. That includes making dumb jokes involving race ... You can call it a 'blind spot for racism' or 'lazy,' but you are wrong. It is a joke ... I am not racist." Schumer was again criticized in July 2020 by Kyndall Cunningham of The Daily Beast for her earlier work, which included "objectifying black men" and calling Latina women "crazy". Cunningham described her "sudden" decision to support the Black Lives Matter movement as "befuddling and laughable". After a fatal shooting took place at a showing of Trainwreck in Louisiana, Schumer advocated for stricter gun control laws and increased mental health funding. After her 2018 wedding, Schumer asked fans to donate to Everytown for Gun Safety instead of giving wedding gifts. In November 2015, Schumer posed nude for a photo by photographer Annie Leibovitz for the 2016 edition of the Pirelli Calendar. Schumer tweeted the photo, writing "Beautiful, gross, strong, thin, fat, pretty, ugly, sexy, disgusting, flawless, woman.
Sources: en.wikipedia.org
György Kéri (Hungarian: [ˈɟørɟ ˈkeːri]; January 11, 1950 – July 20, 2016) was a Hungarian biochemist, professor and Doctor of Biological Sciences (D.Sc.). His major field of research was signal transduction therapy, and he participated in the development of novel drug discovery technologies and drug candidates that entered the clinical development process.
Early lichenologists later reclassified the species in different genera. For instance, Erik Acharius (1803) referred to it as Parmelia parietina in his work Methodus, and Giuseppe De Notaris (1847) listed it as Physcia parietina. Johannes M. Norman (1852) treated it under Teloschistes (a related genus of orange-colored lichens), calling it Teloschistes parietinus. The modern genus Xanthoria was established by Theodor Fries. In 1860, he formally recombined the species as Xanthoria parietina. In his treatment, Fries recognized a distinct form, which he called Xanthoria aureola, distinguishing it from the more common form of X. parietina. He described aureola as a primary and fundamental form of the species, particularly prevalent in Arctic regions, differing from typical X. parietina in its color, rigid thallus, and preference for exposed habitats. Fries also cited Acharius, who considered aureola an intermediate between Xanthoria elegans (now Rusavskia elegans) and X. parietina. These distinctions may have contributed to later taxonomic interpretations that recognized Xanthoria aureola as a separate species. Xanthoria parietina is the type species of the genus Xanthoria. The designated lectotype for Xanthoria parietina is the illustration cited by Linnaeus from Dillenius (1742). Due to its reclassification across different genera, Xanthoria parietina has accumulated many synonyms in the literature. In addition to generic transfers, various infraspecific taxa (forms, varieties, or subspecies) have been described, particularly regarding morphological variants.
The "Cave of the Painters" (Malerhöhle, 画家窟, Cave 207) is one of the earliest caves of Kizil, and one of the most beautiful. The cave contained a statue of the Buddha against the rear wall of the cella, and a barrel-vaulted ambulatory surrounded it. The main cellar contained nine murals of the preaching Buddha on each side wall. The name of the cave comes from the numerous self-portraits of painters standing at the side of the murals, holding paint cupellas and brushes. Several of the painters have a label, such as the written label in Sanskrit (Gupta script): "Painting of Tutuka" ( Citrakara Tutukasya) next to the painter in question. "Citrakara" is not Tocharian, but Sanskrit (and later Hindi, चित्रकला) for "painter/ painting". In the art of Kizil identifying labels were often added to pictures of donors, but never to narrative scenes. Paleography, stylistic analysis and carbon dating combine to give a date of circa 500 CE for these paintings. Some stylistic elements have a strong Classical touch, such as Roman-style friezes at the top of the walls, over scenes of the Buddha. The Cave of the Painters, as some other caves at Kizil, depicts men in caftans with a triangular collar on the right side, and a unique hairstyle. Another marker is the two-point suspension system for swords, which seems to have been a Hephthalite innovation, and was introduced by them in the territories they controlled. These paintings appear to have been made during Hephthalite rule in the region, circa 480–550 CE.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.